We are live on ! Find out more
CMND icon

Clearmind Medicine

6 hedge funds and large institutions have $137K invested in Clearmind Medicine in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more funds holding

Funds holding: 56 (+1)

19% more capital invested

Capital invested by funds: $115K → $137K (+$21.7K)

0% more ownership

Funds ownership: 0%0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
1
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CMND Hedge Fund Activity: Q3 2023 in Review

6 institutional investors reported a position in Clearmind Medicine (CMND) for Q3 2023, worth a combined $137K — up 19% from $115K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CMND positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $147K. The largest seller was Citadel Advisors, cutting an estimated $9.16K.

  • 6 institutional investors held Clearmind Medicine (CMND) as of Q3 2023, up from 5 in Q2 2023.
  • Funds reported $137K of Clearmind Medicine stock for Q3 2023, up 19% quarter-over-quarter.
  • 3 funds opened new Clearmind Medicine positions in Q3 2023 and 2 closed out, a net change of +1 holder.
  • The largest Clearmind Medicine buyer in Q3 2023 was Walleye Capital, an estimated $147K added.
  • The largest Clearmind Medicine seller in Q3 2023 was Citadel Advisors, an estimated $9.16K sold.

Based on aggregated 13F filings for Q3 2023.